SEARCH THE BLOG:
0 comments / 0 votes

Bay Area Health Trust (www.bayareahealthtrust.com), a Hamilton, Ontario based company today announced an exclusive licensing agreement for the ‘McMaster Molecular Medium (“MMM”) with McMaster University. Developed by researchers from St. Joseph’s Healthcare Hamilton‘s Disease Diagnostics and Development Group, MMM will enable labs to safely increase their COVID testing capacity and therefore return results faster. In […]

0 comments / 0 votes
0 comments / 0 votes

n the hopes of averting future pandemics, Hamilton’s McMaster University is connecting a number of its top infectious disease clinicians and researchers worldwide to prevent global health threats like antimicrobial resistance. The goal of the Global Nexus for Pandemics and Biological Threats is to ensure Canada and the world are better able to manage the […]

0 comments / 0 votes
0 comments / 0 votes

Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, […]

0 comments / 0 votes
0 comments / 0 votes

Hamilton’s Fusion Pharmaceuticals Inc. has increased its planned initial public offering on the Nasdaq by half and now hopes to raise up to US$230-million, the biotechnology developer said late Wednesday. The cancer drug developer filed Monday to go public, laying out plans to sell 8.35 million shares at US$14 to US$16 apiece, plus an option […]

0 comments / 0 votes
0 comments / 0 votes

Century Therapeutics today announced its acquisition of Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma (GBM). “We are pleased to welcome the Empirica team to the Century family. Their deep expertise and unique capabilities will allow us to accelerate efforts to develop iPSC derived immune effector cell products designed to treat and […]

0 comments / 0 votes
0 comments / 0 votes

Triumvira Immunologics, Inc. (Triumvira), a Hamilton-based private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its novel T-cell therapy product TAC01-CD19 in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) after at […]

0 comments / 0 votes

Contributing to the latest round of Mariner Endosurgery, Bay Area Health Trust shows strategic support for local health care businesses and ecosystem. HAMILTON, Ontario — Bay Area Health Trust (bayareahealthtrust.com), a Hamilton, Ontario based company that operates life science businesses with the goal of returning value to its beneficiaries including Hamilton Health Sciences announced it […]

0 comments / 0 votes
0 comments / 0 votes

VoxNeuro is excited to announce that the company will receive up to CA$249,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Obtaining NRC IRAP funding not only serves as recognition for VoxNeuro’s focus on innovation, but will serve as a catalyst for the company’s continued […]

0 comments / 0 votes
0 comments / 0 votes

Five professors of the Faculty of Health Sciences have been elected fellows of the Canadian Academy of Health Sciences, considered one of the highest honours for members of the country’s health sciences community. Click here for the full article They have all been chosen through peer review for their demonstrated leadership, creativity, distinctive competencies, and […]

0 comments / 0 votes

Since it was conceived, Versant Ventures has provided enabling support for the design and launch of an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Today Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with $225 million in committed capital. The fund was oversubscribed, […]

0 comments / 0 votes

Archives

> <
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec